Compare MDGL & QNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDGL | QNT |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8B | 15.1B |
| IPO Year | 2005 | 2026 |
| Metric | MDGL | QNT |
|---|---|---|
| Price | $519.09 | $55.24 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $674.45 | N/A |
| AVG Volume (30 Days) | 372.3K | ★ 1.5M |
| Earning Date | 05-06-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $180,133,000.00 | N/A |
| Revenue This Year | $58.39 | N/A |
| Revenue Next Year | $48.55 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $393.61 | $47.06 |
| 52 Week High | $615.00 | $86.79 |
| Indicator | MDGL | QNT |
|---|---|---|
| Relative Strength Index (RSI) | 50.90 | 44.31 |
| Support Level | $498.59 | $51.22 |
| Resistance Level | $545.13 | $72.40 |
| Average True Range (ATR) | 19.22 | 5.46 |
| MACD | 1.86 | 0.23 |
| Stochastic Oscillator | 76.90 | 22.94 |
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.